Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupPlasma cell neoplasmsSarcomasTransplantationDiseaseEwing SarcomaHodgkin LymphomaMantle Cell LymphomaMultiple MyelomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbStem Cell Transplantation, AutologousSubgroupICD10C40.-C41.-C81.-C82.-C82.7C82.9C83.1C83.3C90.-C90.0-Z94.80MeSHHodgkin DiseaseLymphoma, Mantle-CellMultiple MyelomaPlasmacytomaSarcoma, EwingTransplantation, AutologousSequenceMATRIXChemotherapyChemo-substanceBusulfanCarmustineCytarabineEtoposideMelphalanThiotepaTreosulfanChemo-substanceBusulfanCarmustineCytarabineEtoposideMelphalanThiotepaTreosulfanChemo-substanceBusulfanCarmustineCytarabineEtoposideMelphalanThiotepaTreosulfanChemo-substanceBusulfanCarmustineCytarabineEtoposideMelphalanThiotepaTreosulfanNo. Substances124 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronHeparinLevetiracetamParacetamolPegfilgrastimPrednisoloneUrsodeoxycholic acidSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronHeparinLevetiracetamParacetamolPegfilgrastimPrednisoloneUrsodeoxycholic acidSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronHeparinLevetiracetamParacetamolPegfilgrastimPrednisoloneUrsodeoxycholic acidSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronHeparinLevetiracetamParacetamolPegfilgrastimPrednisoloneUrsodeoxycholic acidNo. Substances4567Protocol classificationTherapy classificationcurrent standardIntensityhigh doseHigh dose myeloablativeStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseautologous stem cell transplantationconditioningTherapy intentioncurativesupportiveRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityIncrease AminotransferasesInfectionsMucositisMyositisNeutropeniaOral MucositisPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorCaballero MDDirksen UGoldschmidt HLadetto MWhelan JZulu SDiseaseFollikuläres Lymphom °I-IIIa, ECOG 0-2lokalisiertes Ewing-Sarkom, unter 50 JahreMM Stadium II und III, 18-65 Jahre, ECOG 0-3, ErstlinieNHL, HL, Rezidiv, fehlende Remission nach kurativer Chemotherapieprimär disseminiertes Ewing Sarkom, Alter unter 50Prämedikation der autologen StammzellinfusionOriginDepartment of Hematology, Hospital Universitario Salamanca, SpanienDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy; FLAZ-12EBMT, Cancer Services, Royal Free Hospital, London, UKEuro-E.W.I.N.G.99 and Ewing-2008Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (EWING 2008)German-Speaking Myeloma Multicenter Group (GMMG), Therapieteil analog der HD-3 StudieProtocols in Revision 6 protocols foundProtocols under revision.BEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation, Autologous (PID280 V2.1)Busulfan 1 / Melphalan 140, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID76 V1.1)High-dose Melphalan 200 before Autologous Stem Cell Transplantation, Multiple Myeloma (PID528 V2.2)Melphalan 140 / Treosulfan 12, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID1396 V2.1)Stem Cell Infusion (PID614 V2.0)TEAM - Thiotepa 5 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to Stem Cell Transplantation, Autologous (PID406 V2.0)
